Genflow Biosciences PLC Announces Exercise of Warrants and Issue of Equity
The warrant exercises bring in cash but dilute existing holders; admission of the new shares remains pending.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Genflow Biosciences (GENFF) received notices to exercise warrants for 28,124,999 new ordinary shares, with the subscription funds already received.
The exercises brought in £309,375 in gross proceeds at an adjusted exercise price of 1.1p. The warrant terms provide for a price reset if Genflow completes a lower-priced share issuance or grants rights to subscribe for equity at a lower price during the exercise period. Genflow has applied for admission of the new shares to the FCA official list and LSE main market, expected on or around 8:00 a.m. on 2 October 2026. Following admission, issued shares and voting rights will total 594,534,781.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point£309,375 in gross proceeds from the warrant exercises has been received.
Negative
- Moderate point28,124,999 new ordinary shares at the adjusted 1.1p exercise price dilute existing holders.
- Minor point. Forward-looking: it has not happened yet and may not happen.Admission remains pending and is expected on or around 8:00 a.m. on 2 October 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON, UK / ACCESS Newswire / September 29, 2026 / Genflow (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), a biotechnology company focused on the development of gene therapies for age-related diseases announces that it has received notices of exercise of warrants for a total of 28,124,999 new ordinary shares in the capital of the Company (the "Warrant Shares") with gross proceeds amounting to £309,375.
The Warrant Shares comprise 28,124,999 new ordinary shares being issued pursuant to the exercise of warrants granted and announced on 8 May 2025. As announced, the exercise price of these warrants ("Exercise Price") is subject to adjustment in certain circumstances, as set out in the warrant instrument, including a reset of the Exercise Price (as defined therein) if the Company completes a share issuance (or other transaction granting rights to subscribe for equity securities) during the Exercise Period (as defined therein) at a price lower than the Exercise Price. As such, the Exercise Price was adjusted to 1.1p. Subscription monies of £309,375 have been received by the Company in respect of this exercise.
Admission and Total Voting Rights
Application has been made for the Warrant Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to the FCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 2 October 2026 ("Admission").
The total number of issued shares and the total number of voting rights in the Company, following Admission, will be 594,534,781.
The above figure of 594,534,781 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company, under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Enquiries:
Genflow Biosciences Plc | |
Dr Eric Leire, Chief Executive Officer | +32 4774 95881 |
ON365 Partners Inc. | +1 617-444-9509 |
Eric Laub, Investor Relations |
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies for age-related diseases, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's proof-of-concept clinical trial evaluating its SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction Associated Steatohepatitis), the most prevalent chronic liver disease for which there is a persistent unmet medical need. Genflow is also advancing an ophthalmology program, GF-1006, an mRNA-based SIRT6 therapy targeting corneal pathologies and glaucoma - a leading cause of irreversible blindness for which current treatments reduce intraocular pressure but do not prevent degeneration of the optic nerve. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much did Genflow Biosciences receive from the warrant exercises, and at what price?
Genflow received £309,375 in gross proceeds from exercises for 28,124,999 new ordinary shares at an adjusted exercise price of 1.1p.